Cencora

COR

Market cap $61.9B

Cencora (COR) gets its prior buy rating from 2025 reaffirmed, driven by several strong fundamentals, despite a recent price retreat. The healthcare distributor has a global brand footprint, a key role in serving specific clinical needs, and profitability, despite thin margins. The dividend case is compelling, with proven 10 year growth across many market cycles, and a low payout ratio.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin.

Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.

Drug ​distributor Cencora ‌said on ​Monday ​it would ⁠buy ​the retina ​business of eye ​care ​network EyeSouth ‌Partners ⁠for $1.1 billion, expanding ​its ​eye ⁠care unit.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora's Retina Consultants of America (“RCA”), a leading management services organization (MSO). “Driven by a commitment to empower ophthalmologists, EyeSouth Partners has built a strong regional network of physicians.

Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cen.

Cencora, Inc. (COR) Presents at Leerink Global Healthcare Conference 2026 Transcript

Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Cencora (COR) reported earnings 30 days ago. What's next for the stock?